Sartorius pioneers continuous bioprocessing from single-use
The company's Pionic® platform with Sanofi aims to increase productivity threefold and reduce costs by 50%.
See the latest news and media coverage for Sartorius. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science research and biopharmaceutical technology provider
sartorius.comLast updated
In short: Sartorius reported profitable growth in the first half of 2026, expanded its global manufacturing network, and launched several platforms.
The company's Pionic® platform with Sanofi aims to increase productivity threefold and reduce costs by 50%.
Sales up 6.4% constant currency, EBITDA margin 31.4%, confirms guidance.
Operational sales revenue grew 7.7% in constant currencies and underlying EBITDA margin rose to 30.3%.
The site more than doubles manufacturing capacity for cell and gene therapy materials, cost over €140 million, accommodates up to 180 employees, and operates without fossil fuels.
Sartorius stock trades in a tight range as investors weigh audited full-year 2025 results published on February 16, 2026. The company reported revenue of EUR...
SARTORIUS AG Add to list PDF report Consensus Sartorius AG Xetra Stock 716560 DE0007165607 SRT Medical Equipment ... Overview Quotes...
At the end of August 2026, the Sartorius-Stedim stock holds steady at 195 euros on Tradegate. Following the recent Q...
The shares of Sartorius and its French subsidiary Sartorius Stedim Biotech benefited on Thursday from buy recommendations by UBS.
Track Sartorius and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Sartorius and other trending companies.